Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Polypeptide for preparing antineoplastic antibody and its uses

A tumor and antibody technology, applied in the field of polypeptides for preparing anti-tumor antibodies, can solve the problems of reducing tumor mortality and cell damage

Inactive Publication Date: 2007-04-25
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main methods of clinical treatment of cancer are surgical resection and radiotherapy and chemotherapy. However, while radiotherapy and chemotherapy kill cancer cells, they also cause serious damage to normal cells in the human body.
The three conventional treatment methods of surgery, radiotherapy and chemotherapy for the treatment of malignant tumors have not significantly reduced the mortality rate of tumors, and their 5-year survival rate is only 10-30%. Therefore, countries all over the world are constantly exploring and trying to find more effective treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide for preparing antineoplastic antibody and its uses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Preparation of new human tumor antigens

[0033] According to the prior art and artificial synthesis technology, the amino acid sequence of the antigen described in the present invention is used to synthesize the corresponding polypeptide. (or entrust a synthesis organization to complete) obtain a certain quality of antigenic polypeptides as required. At the same time, the synthetic polypeptide can be coupled to keyhole limpet hemocyanin for future antibody production

[0034] The obtained amino acid sequence is as follows: (SEQ ID NO: 1)

[0035] H2N-Arg-His-Asn-Trp-Gly-Gln-Gly-Phe-Arg-Leu-Gly-Asp-Gln-COOH

Embodiment 2

[0037] Preparation of new monoclonal antibody corresponding to human tumor antigen

[0038] (1) Monoclonal Antibody

[0039] The antigenic protein formed by 100 μg of human tumor antigen polypeptide coupled with keyhole limpet hemocyanin obtained in Example 1 was mixed with complete Freund’s adjuvant to subcutaneously immunize BALB / C mice, and 50 μg of antigenic protein was mixed with complete Freund’s adjuvant after 4 weeks Intraperitoneal booster immunization, 4 weeks later, 50 μg of antigenic protein mixed with complete Freund’s adjuvant was used for intraperitoneal booster immunization again, a total of 3 booster immunizations, blood was collected 10 days later to measure the titer, and the titer was found to be >1:10 6 , the animal was sacrificed, the spleen tissue was collected, and separated into single cells through a 100-mesh sieve. 5 million splenocytes were fused with 1 million SP2 / 0 cells by using 50% PEG to promote fusion. After fusion, HAT medium was used for sc...

Embodiment 3

[0041] Preparation of New Antibody Derivatives Corresponding to Human Lung Cancer Antigen

[0042] (1) Nuclide-antibody conjugates

[0043] (1) 188 Re-labeled new mouse monoclonal antibody corresponding to human tumor antigen

[0044] SnCl 2 The antibody was labeled by direct reduction method, and the labeling efficiency and radiochemical purity of the antibody were determined by rapid thin layer chromatography (ITLC). After labeling, ITLC experiments show that: 188 The Re-antibody labeling rate is 90%, and the radiochemical purity is greater than 95%. 188 Re-antibody specific activity is 356MBq / mg. measured by ELISA 188 Re-antibody immunoactivity was 65%. The in vitro stability experiment of the labeled antibody showed that when the antibody was incubated at 37°C for 24 hours, no matter in normal saline or human serum albumin, the radioactive shedding was less than 5%, indicating that it was stable in vitro.

[0045] (2) 131 I-labeled new human tumor antigen correspo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a polypeptide to prepare tumour-proof antibody and nucleotide sequence to code the polypeptide, which can be applied in kinds of biological agent or relative drugs.

Description

technical field [0001] The present invention relates to a polypeptide which can be used to prepare anti-tumor antibody, and the nucleotide sequence encoding the polypeptide. The present invention also relates to a method for preparing antibodies by using the polypeptide to immunize animals, and also relates to the application of monoclonal antibodies prepared by using this method in the production of various biological agents for treating various related tumors, or the combination with other types of drugs application. Specifically, the present invention relates to a polypeptide sequence of a membrane protein located on the surface of tumor cells and its extracellular region. The monoclonal antibody prepared through the polypeptide can inhibit the function of the protein. The monoclonal antibody is used as a therapeutic agent or A drug combination containing the antibody can inhibit the growth of tumors in vivo and achieve the effect of treating tumors. Background technique...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/435C07K14/47C07K19/00C07K16/18C07K16/28A61K39/395A61K47/48A61P35/00A61K47/68
Inventor 杨治华冉宇靓胡海
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com